CureVac (CVAC) Stock Price, News & Analysis

Company Overview

CureVac N.V. is a biotechnology company focused on developing messenger RNA (mRNA)-based medicines and vaccines. Its research uses mRNA molecules to instruct cells to produce therapeutic proteins or disease-targeting antigens, with the goal of treating or preventing infectious diseases, cancer and other medical conditions.

The company’s development programs have included prophylactic vaccines for infectious diseases, therapeutic cancer vaccines and treatments designed to stimulate the immune system. CureVac has also developed mRNA manufacturing and delivery technologies intended to improve the stability, performance and scalability of mRNA-based products.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has operated internationally through research, clinical development and commercial collaborations. The company became publicly traded in the United States in 2020 through American Depositary Shares listed on the Nasdaq under the symbol CVAC. Its programs and partnerships have involved pharmaceutical and biotechnology organizations in Europe, North America and other global markets.

Key Stats

• Today's Range: $4.66 to $4.66
• 50-Day Range: $4.66 to $4.66
• 52-Week Range: $3.13 to $5.72
• Volume: N/A
• Average Volume: 992,546 shs
• Market Capitalization: $1.05 billion
• P/E Ratio: 6.47
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

CureVac Stock Analysis - MarketRank™

CureVac scored higher than 2% of companies evaluated by MarketBeat, and ranked 895th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

CureVac has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CureVac has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CureVac is 6.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of CureVac is 6.47, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.68.

Price to Book Value per Share Ratio

CureVac has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CVAC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CureVac does not currently pay a dividend.

Dividend Growth

CureVac does not have a long track record of dividend growth.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: N/A

News Sentiment

CureVac has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for CureVac this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CureVac insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.15% of the stock of CureVac is held by insiders.

Percentage Held by Institutions

17.26% of the stock of CureVac is held by institutions.

Company Calendar

• Last Earnings: 11/24/2025
• Today: 10/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CVAC
• CIK: 1809122
• Web: www.curevac.com
• Phone: 49-70-71988-30
• Fax: 49-7071-9883
• Employees: 880
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): $0.72
• Trailing P/E Ratio: 6.47
• Forward P/E Ratio: 6.47
• P/E Growth: N/A
• Net Income: $175.50 million
• Net Margins: 199.92%
• Pretax Margin: 232.79%
• Return on Equity: -23.03%
• Return on Assets: -19.09%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 3.70
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: $70.74 million
• Price / Sales: 14.78
• Cash Flow: $0.99 per share
• Price / Cash Flow: 4.73
• Book Value: $3.36 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 224,338,000
• Free Float: 219,515,000
• Market Cap: $1.05 billion
• Optionable: No Data
• Beta: 1.77